Comparison of Hemodynamic Responses to Acute and Chronic Exercise in Obese and Lean Prehypertensive Men by Zeigler, Zachary (Author) et al.
 
 
Comparison of Hemodynamic Responses to Acute and Chronic Exercise in Obese and 
Lean Prehypertensive Men 
by 
Zachary S Zeigler 
 
 
 
 
 
A Dissertation Presented in Partial Fulfillment  
of the Requirements for the Degree 
Doctor of Philosophy 
 
 
 
 
Approved April 2016 by the 
Graduate Supervisory Committee: 
 
Pamela Swan, Chair 
Glenn Gaesser 
Matthew Buman 
Siddhartha Angadi 
Mookadam Farouk 
 
 
 
 
 
 
ARIZONA STATE UNIVERSITY 
 
May 2016 
i 
 
ABSTRACT 
PURPOSE:  Lean hypertension (HTN) is characterized by a mechanistically 
different HTN when compared to obese HTN. The purpose of this study is to assess 
whether body phenotype influences blood pressure (BP) responses following both acute 
and chronic exercise.  METHODS: Obese (body mass index (BMI) > 30 kg/m2) and lean 
(BMI < 25 kg/m2) men with pre-hypertension (PHTN) (systolic BP (SBP) 120 - 139 or 
diastolic BP (DBP) 80 - 89 mm Hg) were asked to participate in a two-phase trial.  Phase 
1 assessed differences in post-exercise hypotension between groups in response to an 
acute exercise bout.  Phase 2 consisted of a two-week aerobic exercise intervention at 65-
70% of heart rate (HR) max on a cycle ergometer.  Primary outcome measures were: 
brachial BP, central (aortic) BP, cardiac output (CO), and systemic vascular resistance 
(SVR) measured acutely after one exercise session and following two weeks of training.  
RESULTS: There were no differences between groups for baseline resting brachial BP, 
central BP, age, or VO2
 peak (all P > 0.05).  At rest, obese PHTN had greater CO 
compared to lean PHTN (6.3 ± 1 vs 4.7 ± 1 L/min-1, P = 0.005) and decreased SVR 
compared to lean PHTN (1218 ± 263 vs 1606 ± 444 Dyn.s/cm5, P = 0.003).  Average 60-
minute post-exercise brachial and central SBP reduced by 3 mm Hg in Lean PHTN in 
response to acute exercise (P < 0.005), while significantly increasing 4 mm Hg for 
brachial and 3 mm Hg for central SBP (P < 0.05).  SVR had a significantly greater 
reduction following acute exercise in lean PHTN (-223 Dyn·s/cm5) compared to obese 
PHTN (-75 Dyn·s/cm5, P < 0.001).  In lean subjects chronic training reduced brachial BP 
by 4 mm Hg and central BP by 3 mm Hg but training had no effect on the BP’s in obese 
subjects.  Resting BP reduction in response to training was accompanied by reductions in 
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SVR within lean (-169 Dyn·s/cm5, P < 0.001), while obese experienced increased SVR 
following training (47 Dyn·s/cm5, P < 0.001).  CONCLUSION: Hemodynamic response 
to both acute and chronic exercise training differ between obese and lean individuals.     
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     CHAPTER ONE 
INTRODUCTION 
Overview.  According to the World Health Organization, more than a third of the 
world’s deaths can be attributed to a small number of risk factors.  Among the top five 
leading risk factors are hypertension (HTN), obesity and physical inactivity (233).  
Worldwide prevalence of HTN is roughly 1 billion individuals with approximately 7.1 
million deaths worldwide being ascribed to HTN (227).  While the latest guidelines 
addressing BP failed to comment on the category of pre-hypertension (88), the JNC 7 
stated that the most vulnerable population for developing HTN are those classified as pre-
hypertensive (PHTN) (108).  PHTN individuals are twice as likely to develop HTN 
compared to normotensives (108) and are at increased risk for cardiovascular morbidity 
and mortality (28).  However, the only recommended treatment for PHTN is lifestyle 
modification (28).   
It is estimated that at least 75% of the incidence of elevated blood pressure (BP) 
is linked to obesity (3).  Paradoxically, studies suggest that obese (BMI ≥ 30 kg/m2) HTN 
individuals may suffer from fewer cardiovascular events when compared to lean (BMI < 
25 kg/m2) HTN (9, 220).  It appears that the presentation of HTN may be mechanistically 
different between the obese and lean (133, 221).  The classic characteristics of essential 
HTN consist of elevated afterload with normal cardiac output (CO) and its hemodynamic 
trademark is increased systemic vascular resistance (SVR) and contracted blood volume 
(133).  In contrast, obese HTN individuals have been shown to have more of a volume 
overload presenting with a decreased  SVR (221). 
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Most people with elevated BP respond favorably to aerobic training programs 
(156).  In fact, the literature suggests that the greatest drop in resting BP occurs after as 
little as two-to-three weeks of aerobic exercise training (130, 228).  However, the 
magnitude (and therefore clinical relevance) of BP reduction in response to exercise 
training varies considerably (8) and even non-responders to these programs are common 
(17).  It is well documented that an acute exercise bout of moderate-to-vigorous intensity 
can result in a post-exercise hypotensive (PEH) response lasting several hours (6, 12, 23, 
158).  Importantly, the magnitude of one’s PEH response to an acute exercise bout is a 
predictor of how well one may respond to a chronic exercise training program (76, 107, 
120).  The precise mechanisms that underlie the BP reduction in response to exercise are 
not completely clear (23) owing to the complex etiology of HTN and dissimilarities 
across heterogeneous populations.  Clearly to achieve a BP reduction in response to 
exercise, either CO, SVR or a combination of both, must decrease.  However, it is 
unknown how much of the variability in cardiovascular dynamics that present in response 
to exercise are a result of differences in body size (e.g., obese or lean).   
As noted previously, obese HTN and lean HTN individuals may have a 
mechanistically different HTN and this may affect how they respond to acute exercise 
stress.  For instance, during graded maximal exercise Weber et. al. (33) found that while 
the absolute rise in BP in response to increases in exercise intensity was similar between 
lean HTN and obese HTN subjects, BP rise in the lean group was more dependent on 
changes in catecholamine and the renin system when compared to obese (221).  
Moreover, the majority of studies that have assessed the BP response to exercise have 
only analyzed brachial BP, thereby overlooking any potential influence that central BP 
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and/or other hemodynamic responses may play. Central aortic BP has been shown to be 
an independent predictor of cardiovascular structural damage leading to clinical outcomes 
(37, 89, 106, 121, 175).  In other words, variations in central pressure may provide very 
different information about the cardiovasculature than brachial pressure alone.  For 
example, the CAFE (Conduit Artery Function Evaluation) study illustrated that different 
BP lowering drugs had similar effects on brachial BP but significantly different outcomes 
on central BP (229). Thus, to appropriately compare exercise effects between individuals 
with different body phenotype, both central and peripheral hemodynamic responses to 
exercise should be examined.  
Purpose.  There is a growing need to design exercise interventions with the goal 
to reduce the overall public health burden of HTN.  Reductions of just 5 mmHg of SBP in 
the population have been estimated to result in a 14% overall reduction in mortality due 
to stroke, a 9% reduction in mortality due to coronary heart disease, and a 7% decrease in 
all-cause mortality (226).  Currently, there is no published research that has examined 
differences in PEH or the changes in resting BP in response to acute and chronic exercise 
in obese and lean PHTN individuals.  It is currently unknown what influence body 
phenotype may have on both central and peripheral hemodynamic outcomes in response 
to exercise.  Thus, the purposes of this study are to: a) examine potential differences in 
the mechanisms underlying PEH and chronic resting BP changes in response to exercise 
in obese and lean PHTN men, and b) to determine the ability of the PEH response to 
predict resting BP changes following aerobic training in obese and lean PHTN persons.  
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Primary Aim: The primary aim of this experiment is to assess differences in CO, 
SVR, and changes in resting brachial and central BP between inactive PHTN obese and 
lean men following both acute and chronic aerobic exercise.  
Hypothesis: It is hypothesized that PHTN lean and obese men will be 
significantly different in their central and peripheral hemodynamic response following 
exercise such that lean men will have a greater reduction in SVR as compared to obese 
men, whereas obese men will see greater reductions in CO.  It is also hypothesized that 
the magnitude of reduction following acute and chronic exercise between groups will 
significantly differ with lean PHTN responding with a greater reduction in brachial and 
central pressure.   
Secondary Aim: A secondary aim of this experiment is to assess the relationship 
between PEH and resting BP values following two-weeks of aerobic exercise training.   
Hypothesis: It is hypothesized that the magnitude of PEH (greatest brachial SBP 
reduction following an acute bout of exercise) will predict the efficacy of aerobic 
exercise training to reduce resting SBP. 
Exploratory Aim: To assess differences in measures of arterial stiffness between 
obese and lean PHTN men following both acute and chronic exercise training.  
Hypothesis: There will be no differences in measures of arterial stiffness between 
groups following both acute and chronic exercise.    
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CHAPTER TWO 
REVIEW OF LITERATURE 
Hypertension Complications and Mechanisms.  According to the World Health 
Organization, more than a third of the world’s deaths can be attributed to a small number 
of risk factors.  Among the top five leading risk factors is hypertension (HTN) (233).  
Worldwide prevalence of HTN is roughly 1 billion individuals with approximately 7.1 
million deaths worldwide being ascribed to HTN (227). HTN has been found to be 
responsible for at least 45% of deaths due to cardiovascular disease and 51% of deaths 
due to stroke (232).  Long term follow-up from the Framingham study suggest that 
coronary heart disease is more frequent in relation to high blood pressure (BP) than any 
other cardiovascular complication (38).  Conversely, clinical trials have shown that the 
lowering of BP leads to a reduced risk for heart failure in those with elevated BP (119, 
237).  HTN is a contributor not only of heart disease but also stroke, kidney failure, 
mortality, and disability (234).  There are also economic costs for HTN related 
interventions such as cardiac bypass surgery, carotid artery surgery, and dialysis (234). 
 Multiple mechanisms of HTN have been proposed, namely: higher renal 
perfusion pressure required for sodium excretion; impairment of renin-angiotensin 
system activation; increased sympathetic tone; disrupted vasodilation; and age related 
stiffening of central arteries (43).  The kidney is a key player in the development of HTN 
with the prevalence of HTN ranging from approximately 22% in stage 1 to over 80% in 
stage 4 chronic kidney disease (CKD) (225).  HTN is not only a cause but also a 
consequence of CKD (168), introducing a vicious circle of HTN-CKD interrelation and 
subsequently stronger CKD-risk association.  An aging kidney is characterized by 
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vascular changes that decrease blood flow and glomerular filtration rate.  This is also a 
common finding in HTN patients.  In fact, it has been estimated that lifetime risk for 
developing HTN is 90% primarily due to the effects of the aging kidney on HTN (67).  
 The brain is one of the most metabolically active organs in the human body 
accounting for 20% of the body’s resting energy consumption (186).  This high energetic, 
and hence perfusion, demands of the brain imply that it is susceptible to ischemic injury.  
The Framingham study has clarified the role of HTN as a precursor to stroke (98) . 
HTN poses a great deal of arterial pressure that leads to left ventricular 
hypertrophy (LVH) (54).  In the Framingham Heart Study, the presence of LVH was 
associated with a 2- to 5-fold increase in myocardial infarction incidence over 30 years of 
follow-up (96).  LVH is associated with increased morbidity and mortality independent 
of arterial pressure and age (54, 55).  Evidence of LVH is rare in normotensive persons 
(114) whereas those with mild hypertension have a 2- to 3-fold risk for developing LVH 
and those with severe hypertension have a 10-fold increase risk for developing LVH 
(evidenced by electrocardiography) (97).  LVH risk is evident along a full range of 
ventricular mass (115), with few exceptions.  In athletes and healthy individuals LVH has 
not found to be correlated with adverse events (39, 160).  Thus, in HTN, LVH appears to 
reflect changes in quality rather than quantity of myocardial tissue.  Characteristics of 
LVH in HTN are cardiac myocyte hypertrophy, impairment in coronary hemodynamics, 
and ventricular fibrosis. 
HTN has also been shown to correlate with left atrial enlargement, decreased 
atrial contractile function and increase risk of atrial fibrillation (8).  Atrial systole 
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contributes up to 40% of diastolic filling and atrial fibrillation can precipitate overt heart 
failure in patients with underlying ventricular diastolic dysfunction (183). 
In HTN, coronary blood flow is usually maintained but coronary vascular 
resistance is increased (126).  Numerous reports have also shown that the ability of the 
vasculature of a HTN person to dilate in response to stimuli is reduced (126).  For 
example, subjects with HTN and LVH may have exercise induced systolic dysfunction, 
even though left ventricular systolic function is normal at rest (189).  This appears to be 
one of the dominant effects that HTN has on the vasculature, its inability to enlarge in 
response to increased flow. This is more than likely due to arterial structural and 
functional remodeling that occurs with HTN (33).  Increased growth of the media in the 
arterioles, primarily due to smooth muscle hyperplasia, leads to increased vascular 
resistance. 
Another feature of HTN is myocardial fibrosis.  Myocardial fibrosis limits 
coronary perfusion by restricting vasodilation and interfering with relaxation and thus 
diastolic function (179).  This impaired relaxation further limits myocardial perfusion.    
Functional changes in the arterial tree also accompany HTN, most notable are the 
effects on endothelial function (41, 201).  The major factor impacting endothelial 
function is diminished nitric oxide and other vasodilators and increased endothelium 
derived vasoconstrictors.  Impaired endothelial function provides an important 
pathophysiological mechanism to HTN related complications.  
Coronary circulation is affected early in the development of HTN heart disease.  
Impairment in coronary flow reserve and an increase in vascular resistance have been 
found in asymptomatic borderline hypertensive patients with no evidence of LVH (153).  
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Over time the development of LVH and structural remodeling occurs which leads to 
increased impairment in coronary circulation.  
Another characteristic of HTN is increased collagen accumulation in myocardial 
tissue (219).  The mechanisms for the collagen accumulation is not completely 
understood but is thought to be partially explained by the renin-angiotensin aldosterone 
system and salt intake (55, 219).  Animal studies have shown that increased levels of 
angiotensin II or aldosterone develop LVH and fibrosis independent of arterial pressure 
(218, 219).       
Prehypertension. Risk of high BP need not be relegated to only those of the 
HTN status.  Indeed, early population based studies have shown an impact of minor BP 
elevation on the risk of coronary disease (161, 192).  In 1939 Robinson and Bruce found 
that SBP in the range of 120-140 mm Hg was associated with high risk of progression to 
HTN and cardiovascular disease later in life (169).  They referred to those in this BP 
category as prehypertensive (PHTN) (169).  In 2003, The Seventh Report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC-7) incorporated the term “prehypertension” into the guidelines and defined 
it as resting systolic BP values of 120-139 mm Hg or diastolic BP of 80-89 mm Hg (28).   
The latest JNC-8 did not address the use of the term or category of PHTN (88). The 
NHANES III reported that the prevalence of PHTN is 31% while men experience an 
increased risk for PHTN compared to woman (40% compared to 23%) (215). 
 Two landmark studies were integral in the development of this BP category.  A 
meta-analysis of approximately one million people from 61 epidemiological studies 
showed that mortality from ischemic heart disease and stroke in those aged 40-89 yr 
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increases linearly with both systolic BP and DBP (116).  Starting at a BP of 115/75 mm 
Hg there is a two-fold increase mortality risk for every 20 mm Hg increase in SBP and 10 
mm Hg increase in DBP (116).  Secondly, longitudinal data from the Framingham Heart 
Study showed that people with BP values in the PHTN range compared to those with 
values considered normal (less than 120/80 mm Hg) are at increased risk for developing 
HTN and cardiovascular disease later in life (209).    
The use of the term, “prehypertension”, has been somewhat contentious.  In the 
2013 report from the Task Force for the Management of Arterial Hypertension of the 
European Society of Hypertension and the European Society of Cardiology, preference 
was to classify 120-129/80-84 mm Hg as normal and 130-139/85-89 mm Hg as “high 
normal”(123).  The argument for this is that the risk for cardiovascular disease is 
different in those with BP on the lower ends of the PHTN category compared to the 
higher ends.  A 2013 meta-analysis showed that PHTN was associated with significantly 
increased risk of coronary heart disease when compared to those within normal range 
(relative risk of 1.36) (185).  However, when separating the individuals into either high 
PHTN or low PHTN groups, only the high PHTN group showed increase risk for 
coronary heart disease (185).  On the other hand, a separate meta-analysis reported that 
even for low-range PHTN, risk of cardiovascular disease was significantly higher than 
for optimal BP and further increased with high range PHTN (82).   
A 2014 meta-analysis examined PHTN and the risk of all-cause mortality, 
cardiovascular disease, coronary heart disease, and stroke (79).  Fifty articles including 
data on 1,129,098 subjects were included in the analysis.  After adjusting for multiple 
cardiovascular risk factors, PHTN subjects had a relative risk (RR) of 1.28 for 
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cardiovascular mortality, 1.12 for coronary heart disease, and 1.41 for stroke mortality 
compared to those who fell within the normal BP range.  PHTN was not associated with 
all-cause mortality. 
Cross-sectional studies have shown that PHTN, particularly high range, is 
associated with CKD and end-stage renal disease (ESRD) (36, 105, 235, 236).  Cross-
sectional data is problematic in this case particular because renal dysfunction can provoke 
raises in BP.  A 2014 meta-analysis reviewed 22 prospective cohort studies that included 
data from 1,003,793 participants to assess the risk of ESRD among those classified as 
PHTN (80).  Overall, PHTN was associated with increased risk of ESRD (RR, 1.59).  
Even when splitting the group into low PHTN and high PHTN, low PHTN participants 
still exhibited increased risk of ESRD when compared to those with optimal BP (RR, 
1.44).  This risk increased to 2.02 when examining subjects in the high PHTN group. 
Recent work demonstrating the clinical significance of the PHTN category comes 
from the Systolic Blood Pressure Intervention Trial (SPRINT).  Approximately 10,000 
HTN individuals over the age of 50 were randomized to either a BP goal of < 140 mm Hg 
or a more intensive goal of < 120 mm Hg.  Subjects in the conservative goal group 
received an average of two separate antihypertensive medications compared to three 
medications for those in the more intensive group.  Compared to the high BP goal, 
subjects in the lower BP group saw a reduction of myocardial infarction, acute coronary 
syndrome, stroke, heart failure, or cardiovascular death by 30% and the mortality risk 
decreased by almost 25% (145). 
Ample research show that those in the PHTN category are at increased risk for 
risk for stroke (83), coronary heart disease (185), ESRD (80), cognitive impairment (27, 
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46) and cardiovascular morbidity and mortality (81).  Prehypertensive individuals are 
also the most vulnerable population for developing HTN (108).  Indeed, PHTN 
individuals are twice as likely to develop HTN compared to normotensives (108).  Owing 
to this, some have even suggested that drug therapy be initiated within the PHTN group 
to stave off risk (57).  However, the only universal recommended treatment for PHTN is 
lifestyle modification (28).   
Blood Pressure Regulation.  Components of peripheral BP regulation can be 
illustrated by using the following equation, Mean arterial pressure = Cardiac Output (CO) 
X Systemic Vascular Resistance (SVR).  Therefore, anything impacting either one of 
these variables will impact BP.  BP is a somewhat tightly regulated variable in the sense 
that baroreceptors located in areas such as the aortic arch and carotid sinus mechanically 
deform with changes of BP.  These variations will then evoke afferent nerve signals that 
integrate in the brain stem cardiovascular centers causing adjustments in heart rate (HR) 
and efferent sympathetic activity.  These adjustments will then regulate CO and SVR. 
Regulation of BP is not quite as simple however when examining the numerous 
variables that impact SVR and CO.  For example, assuming an upright posture elicits a 
reduction of venous return causing a decreased CO (25). During heat stress cutaneous 
vasodilation causes both a reduction in SVR and venous return, contributing to a fall in 
systemic BP (34).  Long-term changes in blood volume can also play a significant effect 
on BP control via CO.  If blood volume and pressure are low, sodium and water retention 
are increased and if blood volume is high there can be natriuresis and diuresis (33).  The 
aforementioned mechanism is thought to be inappropriately activated in HTN so that 
blood volume and BP are maintained at higher levels.  In this context antihypertensive 
12 
 
drugs such as diuretics target blood volume or elements of the renin-angiotensin-
aldosterone axis.  Lastly, there are marked inter-individual age and sex differences in 
sympathetic vasoconstrictor responsiveness.  For example, elderly men have higher 
baseline levels of muscle sympathetic nerve activity than young men and they also 
vasoconstrict less to a given ά-adrenergic stimulation (181).  In addition, in young men 
there is a tight relationship between baseline muscle sympathetic nerve activity that is not 
seen with young woman (75). 
We also know that BP shows great variability throughout the day in healthy, 
normotensive individuals.  BP is typically the highest in the morning hours and the 
lowest around the hours of 3 pm with about a 30% variation throughout the day (136). 
Many factors affect BP regulation and much heterogeneity in the pathophysiology 
of hypertension exists.  In fact, individuals who share a similar BP value may not 
necessarily share similar risks of cardiovascular events owing to different 
pathophysiology.  This has been documented when examining the physiology of obese 
compared to lean HTN individuals.  
Obesity and Blood Pressure.  Large population based studies have long since 
established BMI as a risk factor for developing HTN (58), with waist circumference and 
waist to hip ratio being more strongly related to HTN (113).  There are many proposed 
mechanisms linking obesity to HTN.  Adipose tissue dysfunction for example, is 
associated with overweight and obesity (66).  Dysfunctional adipose tissue in obesity is 
characterized by hypertrophied adipocytes and changes in secretion of adipokines (66).  
Clinically this is important as decreased levels of adiponectin may provide a direct link 
between obesity and HTN.  Adiponectin is an important stimulator of endothelial nitric 
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oxide synthase, playing a critical role in controlling vascular tone, inflammation, and 
smooth muscle cell proliferation (216).  Adiponectin levels are also independently 
associated with vasomotor dysfunction and thus peripheral vascular resistance (152).   
Obesity induces sympathetic nervous system (SNS) activation (61), which in turn 
may elevate BP by causing peripheral vasoconstriction and impaired pressure natriuresis.  
Leptin, another adipokine, causes reduction in appetite and an increase in SNS activity.  
Obesity is associated with elevated leptin levels but a blunted responsiveness to the 
anorexic effects (144), while sympathetic outflow to kidneys and peripheral vasculature 
is still preserved (163).  When infused into animals, leptin raises BP (184), stimulates the 
SNS (44), and has been shown to correlate with BP in a few human studies (2, 102).   
Overweight and obesity, particularly abdominal obesity, are also associated with 
increased systemic inflammation and oxidative stress (162), both of which are associated 
with arterial stiffness and HTN (180), possibly mediated by endothelial dysfunction 
(191).  
Obesity has also been shown to increase renal sodium reabsorption (68, 69) 
possibly because of heightened sympathetic renal activity (173).  In turn, this could help 
explain the increased plasma volume and CO found in obese individuals (56).  It has been 
found that serum levels of almost all components of the renin angiotensin aldosterone 
system (RAAS) are elevated in obesity (48, 60, 204).  Although RAAS hormones are 
predominately produced elsewhere, adipose tissue has been shown to be an important 
source of RAAS components (48).  In the Framingham Offspring Study, aldosterone was 
positively correlated with both the development of the metabolic syndrome and increased 
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SBP (86).  Sodium aldosterone has also been found to promote sodium retention, 
inflammation, oxidative stress, and insulin resistance (31).   
Comparison Between Obese and Lean Hypertension.  Essential HTN is 
characterized by a normal CO, enhanced contractility, and an elevated afterload with its 
hemodynamic trademark being an elevated vascular resistance (133).  In contrast, in 
obese patients SVR has been found to be decreased and total blood volume expanded.  
Thus, with regard to SVR and total blood volume, the effects of obesity and HTN directly 
offset each other and these hemodynamic measures may be found within normal limits in 
obese persons with essential HTN (131). 
A distinguishing difference between obese and lean HTN is the effect of body 
weight on left ventricular hypertrophy (LVH).  Obesity is characterized by an 
accumulation of excessive amounts of adipose tissue, which in turn increases total body 
oxygen consumption, thus requiring an increase in CO (131).  Because HR remains 
unchanged, the elevated CO is a result from increased stroke volume (SV).  An expanded 
SV dictates an elevated left ventricular end diastolic volume and filling pressure.  As a 
consequence, the left ventricle reacts with dilatation and an increased systolic and 
diastolic diameter.  Chamber dilatation increases wall stress and therefore afterload.  The 
left ventricle adapts to this burden by increasing its muscle mass.  However, this 
increased muscle mass remains proportional to the increase in chamber volume.  Indeed, 
the radius/wall thickness ratio has been documented to remain unchanged in obesity, 
indicating eccentric hypertrophy (111, 112, 231). 
Typically, HTN leads to increasing afterload and this leads to thickening of 
ventricular walls without chamber dilation, or concentric hypertrophy (131).  Systolic 
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pressure is a known determinant of left ventricular mass (178) and correlate inversely 
with the radius/wall thickness ratio in lean subjects.  In contrast, obesity is associated 
with left ventricular dilatation and proportional increase in wall thickness (132).   
Therefore, eccentric hypertrophy results and may override the effects of a patient who is 
HTN and overweight.  Both disease entities increase left ventricular stroke work (obesity 
by increasing SV and arterial HTN by the increase in systolic pressure), the mechanisms 
however differ.  This mechanistic difference between lean and obese HTN has been 
speculated as a possible reason for the obesity paradox seen in relation to obesity, 
elevated BP, and CV mortality.   
Obesity Paradox.  High BP is the leading risk factor for CVD throughout the 
world (117).  In fact, According to the Global Burden of Disease Study, BP and BMI 
combined account for > 60% of the global burden of CVD (50).  These two risk factors 
frequently coexist due, in part, to a causal positive relationship between BMI and BP.  
The prevalence of HTN among the obese is 42.5%, compared to 15.3% among non-obese 
(215).  Investigations purport excess weight gain accounts for 60-70% of essential HTN 
(143).  Studies have shown that a gain in BMI of 2.1/2.7 kg.m2 (men/woman) is 
associated with a 2.2 mm Hg increment in SBP (22), and likewise a weight loss of 1 kg 
results in a 1 mm Hg reduction in BP (147).  There is some evidence that the magnitude 
of the association between BP and subsequent cardiovascular disease or stroke is stronger 
in obese, compared to lean individuals (187).  However, disagreement and controversy 
exists in the literature as to the role that BMI may or may not have on mitigating the 
deleterious effects of elevated BP (187, 202).  Paradoxically, studies suggest obese HTN 
individuals may suffer from fewer cardiovascular events when compared to their lean 
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HTN counterparts (91, 100, 135, 220).  This paradox between obese and lean HTN 
individuals may be explained by the divergent pathogenesis between lean and obese 
individuals (29, 42, 95).   
Early cohort studies suggest that BMI modifies the relationship between BP and 
subsequent risk of coronary heart disease, that is, the relationship between BP and 
vascular risk is diminished with increasing BMI (9, 21, 24, 47, 59, 193, 202).  Subsequent 
cohorts however have produced inconsistent reports (159, 187) and one study of young 
males reported a synergistic effect of BMI on the relationship between BP and 
cardiovascular disease risk (187).  Other studies have reported a U-shaped relationship 
between all-cause, cardiovascular, and non-cardiovascular mortality and BMI, meaning 
excess mortality at both extremes of BMI (193, 203).  Other studies have reported no 
interaction of any sort on BMI, BP, and cardiovascular disease (15, 99, 159).   
In addition to cardiovascular disease, greater risk among lean HTN persons 
compared with obese HTN has also been reported for total mortality (11, 129, 205, 217).  
Uretsky et al. (205) investigated the effects of obesity on cardiovascular outcomes in 
22,576 treated HTN patients with known coronary heart disease.  During a 2-year follow-
up, all-cause mortality was 30% lower in overweight and obese patients, despite less 
effective BP control in these patients compared with the normal weight group. Some have 
postulated that confounding factors such as smoking (smokers tend to have a lower BMI) 
could distort the relationship between BMI, mortality, and BP.  However, in studies that 
control for smoking, excess coronary heart disease risk among lean HTN is still present 
(202). 
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To further illustrate the clinical differences between obese and lean HTN 
individuals, pharmacological treatment variations between BMI groups are addressed.  
Choice of treatment to control BP is typically made without regard to differences in body 
weight between patients. Yet, recognition of clinical and prognostic differences between 
weight categories could affect selection of treatment.  The Avoiding Cardiovascular 
Events through Combination Therapy in Patients Living with Systolic Hypertension 
(ACCOMPLISH) trial has allowed a further look into this hypothesis.  The 
ACCOMPLISH trial was a multicenter trial undertaken at 548 academic centers in the 
USA, Sweden, Norway, Denmark, and Finland.  The purpose of the trial was to compare 
the effects of a combination of an angiotensin-converting enzyme (ACE) inhibitor and a 
calcium channel blocker with the effect of a combination of the same ACE inhibitor with 
a thiazide diuretic.  The primary endpoint was a reduction of cardiac and stroke events in 
HTN patients.  This particular investigation was conducted as a secondary analysis to 
provide insights into the differential effects of treatment on cardiovascular events in HTN 
patients categorized by BMI (220).  Approximately 11,000 individuals were randomized 
to either the ACE inhibitor and calcium channel blocker or the ACE inhibitor and the 
diuretic.  There was a significant difference between weight groups (normal, overweight, 
obese) on the number of cardiovascular events with 7% of patients in the normal weight, 
6% in the overweight, and 5% in the obese group reaching the primary endpoint (P = 
0.025).  Post hoc analysis revealed that the difference occurred between the obese and 
normal weight groups (P = 0.006).  It was also found that there was a significant 
difference between treatment arms for the normal weight (43% risk reduction; P = 0.003) 
and overweight group (24% risk reduction; P = 0.037) in favor of the ACE inhibitor and 
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calcium channel blocker.  These findings indicate two important points; first, 
cardiovascular deaths or non-fatal myocardial infarctions or strokes happen more 
frequently in normal weight than obese HTN patients, and secondly, the type of treatment 
to which patients were randomly allocated were determinants of relations between body 
mass and cardiovascular outcomes.   
Not all studies coincide with the previous findings. The Perindopril Protection 
Against Recurrent Stroke Study (PROGRESS) (165) showed a reduction in risk of 
cardiovascular events across the full range of BMI with the use of perindopril with no 
evidence to support an interaction between BMI and the effect of BP lowering.  A 2015 
review of literature assessed the effects of different BP lowering drugs according to 
baseline BMI (14).  Twenty-two randomized controlled trials that included a total of 
130,000 individuals were included in this review.  The purpose of this analysis was to 
assess if different treatment regimens (pharmacological) between BMI groups favored 
different BMI classes.  This particular analysis did not convincingly show that a 
particular drug class was more or less effective among patients with different BMIs.  
There was a small additional benefit for individuals with higher BMI with ACE 
inhibitors.  This greater protection with ACE inhibitors in obese possibly could be 
explained on the basis of the upregulated state of the RAAS in obesity-mediated 
hypertension (42, 95).  Indeed, ample pharmacological literature indicates that drug 
effectiveness is impacted by a patient’s body weight status, indicating a different type of 
HTN between body phenotype.  
Exercise Response in Obese and Lean.  In addition to different pharmacological 
treatment outcomes between obese and lean HTN, there may be divergent outcomes from 
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physical stress.  In 2001 Weber et al sought to address the question as whether obese and 
lean HTN subjects could be differentiated by their response to a standardized treadmill 
protocol (221).  The hypothesis was that differences in catecholamine and renin values 
might discriminate between obese and lean HTN and that treadmill testing might reveal 
properties that could give further insight to explain differences in the clinical outcomes 
seen between obese and lean HTN individuals.  121 male and female subjects were 
classified into either obese (BMI> 30 kg/m2) HTN, lean (BMI < 25kg/m2) HTN, obese 
normal BP, lean normal BP.  The groups were matched for age and BP.  Baseline blood 
samples were taken for insulin, plasma renin activity, and catecholamines.  In addition, 
renin and catecholamine samples were drawn before and immediately after exercise.  
Baseline echocardiographic studies were also measured on all subjects.  Every subject 
underwent a full treadmill test according to the Balke-Ware treadmill protocol (230).  
There were no baseline differences in renin or catecholamine values and there was no 
difference between groups on left ventricular mass index.  However, assuming a standing 
posture caused a greater increase in norepinephrine in the lean HTN subjects compared to 
the obese HTN subjects.  During the exercise test there was no difference on the maximal 
BP value between groups.  During exercise there was a greater rise in plasma 
norepinephrine and renin activity in the lean HTN group compared to the obese group.  It 
was also shown that at baseline the lean HTN group showed signs of greater arterial 
hardening via the SV/pulse pressure ratio.  This study further adds to what has been 
known and that is that obese and lean HTN are two distinct conditions (166). 
Rockstroth Schmieder, Schachinger, and Messerli (170) also looked at the stress 
response differences between lean and obese HTN individuals using both a mental stress 
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and isometric handgrip exercise.  Subjects with a BMI > 27 kg/m2 were considered obese 
and BMI < 27 kg/m2 were considered lean.  Two stress tests were conducted, first was a 
mental stress test.  Subjects were asked to do basic math while being timed and distracted 
by a metronome in the background.  The second test had the subjects perform isometric 
handgrip at one third of maximal contraction for over three minutes.  At baseline and 
during both assessments, measurements of HR, BP, SV, CO, and SVR were measured.  
During mental stress the obese group was characterized by a slightly higher increase in 
DBP and a significantly increased peak DBP when compared to lean (p < 0.02).  The 
hemodynamic profile in lean HTN during mental stress was characterized by a decrease 
SVR.  In contrast obese was characterized by increase SVR (p <0.03).  The lean HTN 
subjects saw pronounced increases in CO, HR, and SV.  The obese subjects exhibited 
blunted increase in CO and HR (P < 0.05).  Thus in obese HTN, mental stress caused an 
exaggerated increase in SVR and conversely attenuated increase in CO resulting in an 
elevated peak DBP.  The isometric exercise induced a more pronounced increase in SBP 
and DBP in the obese compared to the lean group (P < 0.05).  During isometric stress, 
obese HTN was also characterized by significantly greater increase in SVR compared to 
the lean HTN group.  
It has been known that mental and isometric stress increase BP in both normal and 
HTN individuals.  The mechanisms between the stressors to this BP elevation are 
different.  Mental stress has been shown to cause an increase in CO and HR and a 
decrease in SVR, resulting predominately from epinephrine (63).  In contrast, isometric 
stress is determined by the release of epinephrine and norepinephrine, leading to an 
increase in HR and CO with no change or a slight increase in SVR (118).  Taken 
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together, obesity seems to modify the hemodynamic pattern of response to mental and 
isometric stress: with mental stress, vasoconstriction rather than vasodilation is seen, 
whereas with isometric stress, the response in BP becomes more exaggerated in obese 
HTN than in lean HTN.  
Central Blood Pressure and Central Arterial Stiffness.  For fifty years it has 
been known that end-diastolic BP is nearly identical throughout the arterial tree while 
SBP varies among arterial segments because of arterial pulse pressure amplification (74, 
172, 177).  The result of this is a higher brachial SBP compared to central aortic SBP 
(101). Accordingly, measuring SBP at the brachial artery and assuming transferable 
pressure values in the central circulation is erroneous.  Brachial BP is the product of CO 
and SVR, central BP is more complex and is affected by arterial stiffness and the timing 
and magnitude of the pressure wave (87, 151).  Aortic systolic pressure is determined by 
both cardiac factors (SV and ejection time) and arterial factors (arterial stiffness and 
pulse wave reflection).   
Growing evidence from epidemiological (171, 214) and clinical observation (90) 
suggest that central BP may be more relevant than peripheral BP in predicting target 
organ damage and cardiovascular outcomes.  The population-based Strong Heart Study 
examined 3520 American Indians and found that central pulse pressure was the best 
predictor of common carotid artery and intimal-medial thickness (171).  Similar findings 
have been reported in other population-based studies conducted with Taiwanese (214) 
and South African individuals (148).  In addition to intimal-medial thickness, the 
population-based Taiwanese study (214), Strong Heart Study (171) and the European 
InGenious HyperCar study (146) showed that central SBP was more strongly related to 
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LV mass than brachial SBP.  Waddell et al examined the effect of central pressure on its 
ability to predict coronary artery disease.  114 men were divided into two groups; i) 
moderate (50% to 89% stenosis) or ii) severe (> 90% stenosis). Carotid SBP, but not 
brachial pressures were independent correlates of percent coronary artery narrowing (r = 
0.47; P <0.001) (213).    
Additionally, some drug therapies have been shown to affect brachial BP and 
central BP/hemodynamic properties differently (229).  Thus highlighting the importance 
of knowing both brachial and central BP.  The closer relation of central BP to preclinical 
cardiac and vascular disease is because the loading conditions of the heart and coronary 
vessels are better represented with the central pressure.  Indeed, important information is 
neglected when measuring BP at only the brachial artery with the sphygmomanometric 
method. 
Pulse wave velocity (PWV) has emerged as a valuable tool in the assessment of 
aortic stiffness.  Arterial stiffness increases as elastic fibers in the lamina media of the 
aorta are destroyed and replaced by collagen fibers (109) resulting in an increase in aortic 
impedance and PWV (127).  The properties of the arterial wall, its thickness, and arterial 
lumen diameter are the major factors influencing PWV (174). The Framingham Heart 
Study showed that aortic stiffness, measured as carotid-femoral pulse wave velocity 
(cfPWV) was superior to brachial arterial stiffness, augmentation index, central pulse 
pressure, and pulse pressure amplification on predicting cardiovascular events (137).  
Central femoral PWV is now considered the gold standard for measuring arterial stiffness 
(110).  The 2007 guidelines on the management of arterial hypertension state that the 
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relationship between arterial stiffness and events is continuous, however a threshold of 12 
m/s has been proposed (124).   
Pulse wave analysis (PWA) is the assessment of the augmentation index (Aix), 
which is an indirect measure of arterial stiffness that assesses pulse wave reflection and 
calculates how much of the central pressure is accounted for by the reflected wave pulse.  
This can also be expressed in absolute terms as the augmentation pressure (AP).  
Although PWV and Aix are correlated, they are two different measurements of the 
properties of the arterial tree that cannot be used interchangeably (149).  Aix has not been 
as extensively studied as PWV but has been found to be related to known risk factors of 
CVD (207) and is significantly correlated to the degree of coronary artery disease (222).   
The gold standard for assessing central hemodynamics would be to measure 
directly. However, this is extremely invasive, therefore, several validated methods using 
applanated carotid or radial pulse distension waves have been presented.  The 
SphygmoCor MM3 (ArCor Medical) is a well-validated (1, 154) and extensively used 
system to measure central hemodynamics.  The newer XCELTM device has also been 
shown valid and reliable (84) and uses a simpler, more convenient approach to measure 
arterial stiffness and wave reflection characteristics. 
Using the SphygmoCor XCELTM, PWA can be captured by deriving an ascending 
aortic pressure waveform from the brachial artery waveforms recorded at the arm, using a 
specialized cuff containing a high-fidelity micromanometer. After 10 sequential, high-
quality waveforms (software derived from an algorithm including average pulse height, 
pulse height variation, diastolic variation, and the maximum rate of rise of the peripheral 
waveform) are acquired, a validated generalized transfer function is used to generate the 
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corresponding central aortic pressure waveform.  AIx is influenced by HR, due to this, an 
index normalized for a HR of 75 beats/minute (AIx at HR75) is typically used.  
Carotid-femoral pulse wave velocity (cfPWV) can also be determined by using 
the SphygmoCor XCELTM. The cfPWV is measured by simultaneously recording carotid 
artery wave forms by applanation tonometry and femoral artery waveforms using a 
specialized micromanometer equipped cuff. Distances from the carotid sampling site to 
the suprasternal notch and from the suprasternal notch to the femoral cuff are measured 
as straight lines between the points on the body surface using a tape measure. The 
distance from the femoral arterial pulse to the femoral cuff is obtained and subtracted 
from the total distance (D). The time (t) between the onset of femoral and carotid 
waveforms is determined as the mean from 10 consecutive cardiac cycles. The cfPWV is 
calculated from the distance between measurement points and the time delay (t) as 
follows: PWV = D/t (m/sec), where D is distance in meters and t is the time interval in 
seconds.  
Endothelial function.  It is now understood that central arterial stiffness precedes 
the development of hypertension (94, 223).  Arterial stiffness is greater in the obese than 
in the lean and obese individuals are more likely to have increased aortic stiffness 
independent of BP levels, ethnicity, and age (176).  However, arterial stiffness may not 
be linked to obesity per se, but specifically to central adiposity (51, 52).  The 
physiopathology of this is not completely understood, but it is known that visceral 
adipocytes have elevated lipolytic activity resulting in increased free fatty acids released 
into the portal vein contributing to insulin resistance (176).  Other hypotheses focus on 
increased circulating proinflammatory cytokines or leptin (188, 210).  Leptin has been 
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shown to exert receptor-mediated influence on vessel tone and growth and, in cell 
culture, stimulate vascular smooth muscle proliferation and migration (150).  Another 
factor proposed to explain increased stiffness in abdominal obesity is nitrite oxide (NO) 
disturbance (176). Endothelial dysfunction is characterized by a reduced bioavailability 
of endothelium derived NO and has been found to be associated with arterial stiffness 
(128).  
The gaseous mediator NO plays a key role in protection against cardiovascular 
disease.  NO is produced when L-arginine is transformed to L-citrulline via the catalysis 
of eNOS.  Endothelial eNOS eventually is activated for NO synthesis.  NO prevents 
abnormal constriction of the coronary arteries, inhibits aggregation of platelets, the 
expression of adhesion molecules, and the adhesion and penetration macrophages (208).  
When NO availability is hampered, the inflammatory response (49) that may lead to 
atherosclerosis is set into motion (212).  Both acute and chronic increases in shear stress 
exerted on the arterial wall augment the release of NO (20).  The acute effect of this 
increased shear stress on NO release stimulates Flow-Mediated Dilation (FMD), a 
response used in humans to estimate the functional state of the endothelium.  FMD is a 
non-invasive measurement of endothelial function and correlates closely with the gold 
standard intra-coronary or intra-brachial infusions of vasoactive agents (4, 200).  The 
chronic effect of shear stress on the endothelium explains the beneficial effects of 
exercise on endothelial function (35). 
Endothelium-dependent vasodilation has been found to be blunted in hypertensive 
humans and probably reflects the premature aging of the vasculature being chronically 
exposed to increased arterial BP (208).  Other factors affecting endothelial dysfunction in 
26 
 
obesity may be explained by adipokine dysfunction (199).  As with central 
hemodynamics, of greater importance than total body fat, is abdominal obesity.  It has 
been shown that in healthy overweight adults an increased waist- to-hip ratio is a strong 
predictor of vascular endothelial dysfunction, independent of other cardiovascular risk 
factors (18).  Insulin resistance has been identified as a pathogenic mechanism for the 
development of endothelial dysfunction (103, 194).  In fact, obesity in the absence of 
insulin resistance has not been found to cause endothelial dysfunction (45).   
It is generally recognized that endothelial dysfunction is the first step leading to 
arteriosclerosis (139, 208).  The prognostic value of brachial FMD on cardiovascular 
events and all-cause mortality, that is FMD is an independent predictor of CV events and 
all-cause mortality, have been demonstrated in three meta-analyses (85, 164, 195).  
Indeed, just a 1% increase in FMD showed a relative risk of future cardiovascular events 
of 0.872 (85). 
 Aerobic Training and Cardiovascular Outcomes.  Most people with elevated 
BP respond favorably to aerobic training programs (156).  Aerobic exercise training has 
been shown to reduce resting BP 5 – 7 mm Hg among those with HTN (197).   This 
magnitude of reduction rival’s decreases obtained from first line antihypertensive 
medications and lowers heart disease risk by 20-30% (88).  In fact, the literature suggests 
that the greatest drop in resting BP occurs after as little as one-to-three weeks of aerobic 
exercise training with no further decrease thereafter (130, 142, 228).  Because of this, 
aerobic exercise is encouraged by many national health organizations including the 
American College of Sports medicine who advocate moderate intensity aerobic exercise 
for 30 – 60 min or more on most, preferably all, days of the week to lower BP (157).  
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However, the magnitude (and therefore clinical relevance) of BP reduction in response to 
exercise training varies considerably (8) and even non-responders, upwards of 25%, to 
these programs are common (17).  Bouchard et al. consolidated data from six large 
exercise studies and found that 12% of the sample actually increased BP (> 10 mm Hg) 
in response to exercise training (16).  These data illustrate the critical need to identify 
factors that explain the heterogeneity of exercise response on BP.  Few predictors have 
been explored such as, initial resting BP (those with higher BP will see greater 
reductions), magnitude of PEH (77, 107, 120), BP response to de-training (138) and 
presence or absence of the metabolic syndrome, those without the metabolic syndrome 
respond better (155). 
The precise mechanisms that underlie the BP reduction in response to exercise are 
not completely clear (23) owing to the complex etiology of hypertension and 
dissimilarities across heterogeneous populations.  Clearly to achieve a peripheral BP 
reduction in response to exercise, either CO, SVR or a combination of both, must 
decrease. However, it is unknown how much of the variability in cardiovascular 
dynamics that present in response to exercise are a result of differences in body size 
phenotype (e.g., obese or lean).   
Studies examining the effects of exercise on endothelial function are equivocal, 
more than likely due to various duration of exercise protocols.  Short term aerobic 
exercise training has been shown to enhance eNOS and NO bioactivity (40) while long 
term training induces structural adaptations resulting in an increased arterial size (19).  It 
has been proposed that long term training studies fail to capture functional changes, via 
FMD, because structural adaptations occur, normalizing shear rate levels causing 
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endothelial function to return to normal levels.  Tinken et al had 20 men exercise for 8 
weeks while measuring FMD every two-weeks (198).  It was found that exercise-induced 
functional changes in conduit arteries precede structural adaptations and that brachial 
artery endothelial function initially increased in response to exercise training while 
peaking after two-weeks (6 sessions) of training. 
Generally speaking, exercise training in those with known risk factors of CVD 
has been found to increase endothelial function, while exercise training in healthy 
subjects with normal endothelial function does not provoke changes to the endothelium 
(62).  Beneficial changes on the vascular endothelium are thought to be caused by 
exercise increased NO-synthase protein expression and phosphorylation (73). 
A 2014 meta-analysis (7) examining the effect of different exercise training 
modalities on arterial stiffness found that aerobic exercise significantly reduced PWV by 
-0.63 m/s.  Additionally, they established that aerobic training caused greater reductions 
in peripheral arteries (brachial-ankle PWV) in comparison with central arteries (cf-PWV) 
and those with stiffer arteries (PWV >8 m/s) saw greater reductions in PWV.  In addition, 
training that lasted longer than 10-weeks showed the best benefit on PWV.  It has been 
shown that every 1 m/s increase in PWV is associated with a 12-14% increase risk of CV 
events and 13-15% increase risk of CVD mortality (211).  The 0.63 m/s decrease seen 
from aerobic training could lead to an 8% reduction in CV events and a 9% reduction in 
CV mortality.  In addition to PWV, it was concluded that aerobic exercise training 
significantly lowered Aix by 2.63%.  Interestingly they found that exercise intensity 
rather than volume was positively associated with improvement in Aix.  This analysis 
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included only randomized controlled trials and included studies with subjects classified 
as obese, prehypertensive, hypertensive, diabetic, and chronic kidney disease.  
In contrast, other meta-analyses failed to find positive effects of aerobic exercise 
on arterial stiffness in prehypertensive, HTN (141), and obese (140) participants unless 
associated with reductions in SBP.  These two studies included non-randomized 
controlled trials into their analysis, possibly explaining the differing conclusions.  
Acute Exercise and Blood Pressure.  It is well documented that an acute 
exercise bout of moderate-to-vigorous intensity can result in a post-exercise hypotensive 
(PEH) response lasting several hours (12, 23, 70, 122, 158) with the greatest fall in BP 
occurring within the first hour following (5, 77).  
Taylor-Tolbert et al. (196) recruited 11 sedentary obese hypertensive subjects to 
examine the duration of BP reduction after an acute bout of aerobic exercise.  The study 
was a crossover design in which all subjects performed a control day and an exercise day. 
Exercise consisted of 45 min of aerobic exercise at 70% VO2 peak.  Ambulatory BP was 
recorded for 24-h after exercise and on a separate non-exercise day for the control.  It was 
found that SBP was lower by 6 to 13 mm Hg for the first 16 h after exercise when 
compared to the control day.  Significant reductions were also seen in DBP 16 hours and 
over the course of the 24 h after exercise.  It was concluded that a single bout of moderate 
intensity aerobic exercise significantly lowered BP in obese sedentary hypertensive men. 
PEH is consistently witnessed in HTN and PHTN subjects with varying findings 
in normotensive populations (122). However, it has been suggested that differences 
between normotensive and hypertensives more than likely reflect quantitative rather than 
qualitative differences (70).   
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Most literature suggest that exercise intensity is not a critical factor on PEH (53).  
Nonetheless, a recent article published in 2015 showed that aerobic interval exercise 
(four 4-minute intervals at 90% HR max separated by 3 min recovery) was superior to 
steady state exercise (70-75% HR max) and anaerobic sprint interval exercise (30-second 
Wingate) on both magnitude and duration of PEH (5).  High intensity exercise may be 
superior to lower intensities on provoking PEH.  Nevertheless, the other end of intensity 
spectrum has documented extremely low activities such as standing (238) and walking at 
1 mph (239) lowering ambulatory BP when compared to a non-activity seated day.   
Importantly, the magnitude of one’s PEH response to an acute exercise bout is a 
predictor of how well one may respond to a chronic exercise training program (76, 107, 
120).  This is imperative as it has been identified that as many as 25% of people with 
elevated BP do not see BP reductions following endurance training (65).  Applying this 
relationship may help identify “non-responders” to chronic exercise.  A paper published 
in 2012 by Liu and colleagues (120) and another in 2013 by Hecksteden (77) first showed 
this relationship between PEH and chronic endurance training in small groups of 
prehypertensive individuals.  The magnitude of PEH was strongly correlated with change 
in resting BP values (r=0.89 p< 0.001, r = 0.75 p < 0.001, respectively, data derived from 
(120)).  A 2015 paper replicated the same study question with an increased sample size (n 
= 116) and a population with coronary artery disease (107).  Similar results were found in 
relation to SBP but there was not a significant association between diastolic PEH and 
chronic training response.  A weakness of all three studies were that there were no 
measurements into possible mechanism responsible for the PEH such as systemic 
vascular resistance, arterial stiffness, and endothelial function. 
31 
 
Fractionized exercise has shown superior to one bout of exercise at eliciting PEH 
(6, 12, 224).  Weltman et al. (224) examined the BP response to fractionalized (three 
bouts separated by time) exercise compared to a single session. Sedentary normotensive 
to prehypertensive adults were enrolled in the study.  Participants were randomly 
assigned to either a 1 x 30-minute session or 3 x 10-minute session at a VO2peak of 60-
70%. The 1 x 30-minute exercise session was performed from 0900-0930; the 3 x 10-
minute sessions were initiated at 0920, 1320, and 1720 hours. All subjects performed 
both sessions in addition to a control day.  BP was taken hourly from 0900 to 2100 hours 
by an automated cuff.  Between readings the subjects were at bed rest.  It was found that 
when compared to the control and the 1 x 30 day, fractionalized exercise had consistently 
lower SBP in the afternoon and early evenings. Authors concluded that repeated exercise 
bouts may be superior to one exercise bout to reduce SBP in those with slightly elevated 
BP.  PEH was not observed in the 1x 30 group.  This is thought to be due to inconsistent 
findings of PEH within the normotensive population and the timing of the exercise (122).  
Exercise in the afternoon has been found to have a stronger effect on PEH than exercise 
in the morning (93).   
Mean arterial pressure is the product of CO and SVR.  In the majority of cases, 
indices of systemic and regional resistance are reduced below pre-exercise values during 
the hypotensive period (122).  Conversely, CO is most often elevated during PEH (71).  
However, in different populations this may not be the case.  It has been shown in elderly 
men that post exercise peripheral resistance may actually be increased (64).  Also, in 
endurance trained men CO has shown to decrease below pre-exercise values but not in 
woman (182).  Except in endurance trained men (182), stroke volume remains unchanged 
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during the PEH period following exercise (72).  This leads to the understanding that the 
mechanisms for PEH are different in heterogeneous populations.  Mechanisms of PEH in 
differing populations warrant further investigation as divergent mechanisms may provoke 
a greater magnitude and duration of PEH. 
Studies have shown lessened peripheral resistance at sites other than the 
functioning musculature suggesting that there could be a whole body effect (122).  It is 
known that immediately following exercise there is a brief period of hypotension due to a 
pooling of blood in the vasodilator muscle beds (122).  The mechanisms for PEH are 
dissimilar from this immediate response witnessed post-exercise. Other possible 
mechanisms could be resetting of baroreceptors, changes in thermoregulation, blood 
volume, afferent nerve activity, and circulating hormones expressed from an exercise 
bout.  A 2012 paper by Halliwill et al. (70) indicated that much of the PEH can be 
explained by histaminergic vasodilation, primarily due to the H1 and H2 receptors.  
Histamine is released in the muscle due to mast cells located in the connective tissue 
around the muscle degrading and releasing histamine (134).  It was shown that blockade 
of these receptors but not removal of the sympathetic component reduced PEH.  
Combined H1 and H2 receptor antagonism reduced post-exercise vasodilation by roughly 
80% and reduced PEH by 65% (70). It has been suggested that the histamine 
upregulation associated with PEH may play a role in angiogenesis showcasing other 
clinical benefits of the PEH response (70).   
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CHAPTER THREE 
METHODOLOGY 
Brief Procedures. The study was an experimental design with two phases.  
Figure 1 gives graphical depiction of the research design.  Two groups of subjects were 
selected via volunteers from e-mail list serves and consisted of obese and normal weight 
men with PHTN.  Phase 1 consisted of baseline measures and measures following an 
acute bout of moderate exercise.  Phase 2 consisted of a two-week exercise intervention 
where all subjects were prescribed the same exercise prescription (65-70% of HR max, 
3x/week for 2-weeks) on a cycle ergometer.  All exercise sessions were performed in the 
laboratory under supervision of one of the researchers.  Before and after the exercise 
intervention central and brachial BP, CO, SVR, cfPWV, PWA, and FMD were taken.  
PEH was assessed following the first exercise session and again following the last (sixth) 
exercise session. The post-intervention measurements were taken both 24–hours (h) and 
48-h after the last exercise session to ensure no acute exercise carry over effect.    
Subjects were asked to refrain from any addition physical activity over the course of the 
study.  
Subjects.  20 inactive (defined as less than 60 minutes of moderate to vigorous 
physical activity per week) PHTN (systolic BP (SBP) 120-139 mmHg or diastolic BP 
(DBP) 80-89 mmHg) men were recruited and grouped by body mass index (BMI) and 
waist circumference into obese (BMI ≥ 30 kg/m2 and waist circumference >94 cm) or 
“lean” (BMI < 25 kg/m2 and waist circumference <94 cm) for this experimental study.  
Sample Size Calculation.  Sample size was calculated using a 2-sided 
hypothesis, α= 0.05 and β= 0.20.  Previous work using changes in SVR between lean and 
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obese in response to acute exercise provided the estimates (170).  It is estimated that an 
acute bout of exercise will provoke a 5% SVR mean difference between lean and obese 
with a standard deviation of 5%.  It is estimated that 7 subjects per group will be needed 
to adequately power the study.  Thus, accounting for a 30% drop out, 10 subjects per 
group (20 total) was needed for this study.  
Inclusion Criteria.  Obese (BMI ≥ 30 kg/m2 and waist circumference ≥ 94 cm) 
and lean (BMI < 25 kg/m2 and waist circumference < 94 cm), inactive (< 60 min of 
moderate to vigorous physical activity/week, verified by accelerometer), men aged 18-35 
yr, and PHTN were included.  Waist circumference was used in addition to BMI due to 
the heterogeneity of the obese phenotype and criticism of prior similar research that only 
use BMI to determine obesity status (30).   
Exclusion Criteria.  Those in the “overweight” BMI category (i.e., 25-29.9 
kg/m2) or those with a BMI < 18.5 kg/m2 or > 40 kg/m2 were not included in this study.  
Men over 35 yr old or who registered more than 60 minutes/week of moderate to 
vigorous physical activity were excluded.  Those who answered positively (i.e., yes) on 
any question of The Physical Activity Readiness Questionnaire (PAR-Q) were excluded 
from participating in the study.  Those with known cardiovascular, pulmonary, renal or 
metabolic disease, or having symptoms suggestive of these diseases (data were obtained 
via health history questionnaire) were excluded from the study.  Current smokers or 
anyone with contraindications to vigorous exercise were excluded from the study as well.  
Subjects on medications used for the treatment of cardiovascular disease were excluded.  
Study Design, Visit 1 (Initial Screening Day).  See figure 1 for schematic 
representation of study design.  Subjects had their waist circumference, weight and height 
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measured to determine if their BMI and WC were within the inclusion categories.  Those 
who meet the initial criteria were asked to sit quietly for 5 minutes and then a traditional 
BP measurement was taken on both left and right arms using an automated BP monitor 
(Dinamap® PRO 100 Vital Signs Monitor, GE Healthcare) according to the protocol 
described by the World Health Organization (227).  Two additional BP measurements 
(three total) were taken at 5-minute intervals on both arms.  The arm with the highest BP 
was used to determine baseline BP value.  If the average BP from these three measures 
were within the PHTN range, then subjects were asked to return to the lab for a second 
screening.  In addition, health risk assessment and PAR-Q were used to screen subjects 
for exclusion criteria previously listed.  Subject’s physical activity was screened via the 
Stanford Leisure-Time Activity Categorical Item (L-cat) (104). 
To ensure subjects did not change physical activity behavior over the course of 
the study, participants were asked to wear an activity monitor for seven days prior to the 
study and over the course of the two-week intervention period.  Activity monitors were 
given to participants after the first visit.  Subjects were equipped with a small 
multisensory activity monitor (Sensewear Pro3 armband) positioned over the right triceps 
brachii muscle of the right arm at the midpoint between the acromion and the olecranon 
processes.  The activity monitor collects physiological data from the following sensors; a 
2 axial accelerometer, a heat flux sensor, a skin temperature sensor, and a galvanic skin 
response sensor.  The monitor uses an onboard algorithm (Inner View TM Professional 
software 7.0) fitted with anthropometric data from participants (gender, age, height, and 
weight).  Subjects were given activity logs and asked to report wake time, sleep time, and 
any time the device was removed for longer than 20 minutes.  Daytime energy 
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expenditure, steps, time spent in moderate activity (3-6 METS), and vigorous activity (> 
6 METS) were collected for each week.      
Visit 2 (2nd BP Screening, Baseline Measures).  Three to five days from the first 
screening visit, subjects returned to the lab for three additional BP measurements 
(measures will be performed as previously indicated for Visit 1).  The total of the six BP 
measurements (3 from visit 1 and 3 from visit 2) were averaged together to determine if 
subjects met the PHTN criteria.  Subjects were then directed to have a whole body Dual-
energy X-ray absorptiometry (DXA) scan to determine body composition.  For the DXA 
assessment, subjects were asked to wear metal-free clothing and to remove any jewelry 
while lying face up on the DXA scanner bed for approximately 7-10 minutes.  DXA was 
conducted by a certified radiology technician.  Following the DXA scan subjects 
completed a VO2 peak assessment on an electronically braked cycle ergometer. 
VO2 Max Assessment. All subjects performed a ramp-style maximal exercise test 
on a cycle ergometer at baseline.  Subjects were equipped with a mask attached to a hose 
connected to a mixing chamber for the metabolic measurement device (Parvo Truemax 
2400TM, Parvomedics, Sandy, Utah) to measure ventilation and respiratory gas exchange 
data and wore a Polar heart rate monitor to measure heart rate (HR) continuously. The 
Parvo Truemax 2400TM has shown high validity and reliability (10). The metabolic cart 
was calibrated using the standard three-point calibration before each test. After collecting 
resting data for 2 minutes, subjects performed a 5-minute warm-up at 50 Watts on the 
cycle ergometer, pedaling at a cadence of their choice (subjects were encouraged to 
maintain this cadence for the remainder of the test).  After the warm-up phase, load was 
increased by 30 watts every minute until the subject could not continue.  Verbal 
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encouragement was given to all subjects throughout the entire test. The average of the 
two highest consecutive 15-second oxygen uptake averages during the test was taken as 
the peak VO2.  
Visit 3 (Phase 1 Acute Exercise Response).  Previous research has established 
that the greatest PEH response occurs in the afternoon hours compared to the morning 
hours (92). To control for potential diurnal effects and maximize the PEH response, visit 
three was performed at the same time of day (± 30 minutes) in the afternoon 
(approximately 1 pm). Participants were fasted for at least 5 h, asked to refrain from 
caffeine and alcohol for 24 h and asked to refrain from unaccustomed physical activity 
for 48 h prior to their visit to avoid potential carry over effects from previous activity. 
Subjects were instructed to avoid antihistamines for 5 days prior to each visit to avoid the 
actions of these agents on the vasculature (125).  Oral vitamin C supplementation was 
restricted for 3 days prior to the study.  Subjects were asked to eat their breakfast no later 
than 8 am the morning of this visit and the morning of the post intervention measurement. 
Subjects were asked to consume the same dinner and amount of fluids the night before 
visit three and the post-intervention measurements and the same breakfast and fluids the 
morning of visit 3 and the post-intervention measurements.  Subjects were asked to 
record their meals to ensure compliance with this requirement.  Liquids were tracked via 
instruction to the subjects to drink from a bottle with a known quantity, and to maintain 
that quantity between visit three and the post-intervention measurements.   
Acute Exercise Assessments.  Upon arrival at the research facility subjects were 
directed to lie supine for 20 minutes to achieve hemodynamic stability.  Baseline 
measurements of cfPWV, PWA, central and brachial BP, CO and SVR (measured non-
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invasively via the PhysioFlow) were then assessed.  Following baseline measures, 
subjects performed a 40-minute exercise bout on a cycle ergometer at a HR that elicited 
65-70% of their measured VO2peak.  To warm up, subjects began cycling at a light work 
rate of approximately 25 watts for 5 minutes.  Wattage then increased to elicit the desired 
HR.  Work rate was adjusted if needed to keep HR within ± 5 beats of this value. 
Subjects were given a 5-minute cool-down period at approximately 25 Watts.  Following 
exercise, subjects remained in the laboratory for an additional hour in a supine position.  
Central BP, brachial BP, and PWA was measured every 5 minutes following exercise for 
one hour (12 total measures).  cfPWV was measured twice following exercise, 30 
minutes and then 60 minutes following exercise.  The PhysioFlow remained connected to 
the subjects throughout the entire visit and data was collected in 10-second averages.  
The time frame of measurement was chosen due to previous research illustrating the 
greatest hypotensive response to acute exercise is within the first hour (190).  
Visits 4-8 (Phase 2: Aerobic Training): Subjects returned to the laboratory for a 
total of 6 exercise days (i.e., visit 3 plus 5 additional days) over two weeks.  All training 
was completed at the laboratory under direct supervision of one of the investigators.  
Subjects were equipped with a HR monitor and then asked to perform a 40-minute 
exercise bout on a cycle ergometer at a HR that elicits 65-70% of their measured 
VO2peak.  To ensure exercise prescription adherence, subjects were provided verbal and 
visual HR feedback and encouraged to maintain this value for the entire exercise bout. To 
warm up, subjects began cycling at a light work rate of approximately 25 watts for 5 
minutes.  Work rate was adjusted if needed to keep HR within ± 5 beats of this value.  
Subjects were given a 5-minute cool-down period at approximately 25 watts. 
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Following visit 8 (6th and last training session) post-exercise hemodynamic 
response to exercise was assessed once again.  Subjects were asked to remain in the 
laboratory for an additional hour in a supine position while the same measurement 
protocol as described above was followed.   
Visit 9 and 10 (Assessment of Aerobic Training Response): At 24 and 48 h 
following the last exercise session, subjects were asked to return to the laboratory for 
final cardiovascular measurements.  Upon arrival subjects were directed to lie supine for 
20 minutes to achieve hemodynamic stability.  Measurements of cfPWV, PWA, central 
and brachial BP, CO and SVR were taken as previously described.   
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Measurements.  CO and SVR were measured continuously at visit three and the 
post-intervention measurement via the PhysioFlow device (Manatec Biomedical, Paris, 
France).  The PhysioFlow has been found valid and reliable at rest and during low- to 
maximal-intensity exercise in normal weight, and overweight individuals (26, 167).  The 
PhysioFlow uses changes in transthoracic impedance during cardiac ejection to calculate 
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SV, which is multiplied by HR to provide an estimate of CO.  Sensors on the neck, chest, 
and back are used to transmit and detect electrical and impedance changes in the thorax 
(see figure 2).  This is used to measure and calculate hemodynamic parameters. The 
following procedures have been detailed prior (26) but summarized below.  Subjects 
were directed to lie supine in a quiet, temperature-controlled room, and prepped to have 
two sets of two electrodes placed on the body.  One “transmitting” electrode and one 
“sensing” electrode was be placed above the supraclavicular fossa at the left base of the 
neck and along the xiphoid process, respectively. Another set of two electrodes are used 
to monitor a single ECG lead (V1/V6 position).  SBP/DBP were measured automatically 
via the SphygmoCor device from the brachial artery at rest and every 5 minutes following 
exercise and transferred into the impedance cardiograph device, which calculates mean 
arterial pressure to estimate SVR. 
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Figure 2.  Pictorial representation of electrode placement of PhysioFlow device 
Pulse wave velocity (PWV)/pulse wave analysis (PWA).  Central/brachial BP, 
cfPWV, and PWA measurements were taken using the SphygmoCor XCELTM (AtCor 
Medical, Sydney, NSW, Australia) by means of validated methodology (206).  The 
SphygmoCor MM3 (ArCor Medical) is a well-validated (1, 154) and extensively used 
system.  The newer XCELTM device has also been shown valid and reliable (84) and uses 
a simpler, more convenient approach to measure arterial stiffness and wave reflection 
characteristics.  All measurements were taken in the supine position in a quiet, 
temperature-controlled room after 20 minutes of rest and 2 sequential arterial BP 
measurements that confirm hemodynamic stability.  
43 
 
PWA was performed by deriving an ascending aortic pressure waveform from the 
brachial artery waveforms recorded at the arm, using a specialized cuff containing a high-
fidelity micromanometer. After 10 sequential, high-quality waveforms (software derived 
from an algorithm including average pulse height, pulse height variation, diastolic 
variation, and the maximum rate of rise of the peripheral waveform) are acquired, a 
validated generalized transfer function is used to generate the corresponding central 
aortic pressure waveform. The Aix is calculated as the difference between the first and 
second systolic peaks of the ascending aortic waveform expressed as a percentage of the 
central pulse pressure (the difference between central systolic and diastolic pressure). 
Because Aix is influenced by HR, an index normalized for a HR of 75 beats/minute (Aix 
at HR75) will be used.  
Carotid-femoral pulse wave velocity (cfPWV) was determined by simultaneously 
recording carotid artery wave forms by applanation tonometry and femoral artery 
waveforms using a specialized micromanometer equipped cuff.  Distances from the 
carotid sampling site to the suprasternal notch and from the suprasternal notch to the 
femoral cuff was measured as straight lines between the points on the body surface using 
a tape measure. The distance from the femoral arterial pulse to the femoral cuff was 
obtained and subtracted from the total distance (D). The time (t) between the onset of 
femoral and carotid waveforms is determined as the mean from 10 consecutive cardiac 
cycles. The cfPWV is calculated from the distance between measurement points and the 
time delay (t) as follows: PWV = D/t (m/sec), where D is distance in meters and t is the 
time interval in seconds.  
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Statistical Analysis. Data was analyzed using SPSS software (version 20).  Data are 
expressed as ± standard deviation (SD).  All P values were calculated assuming two-
tailed hypothesis; P < 0.05 is considered statistically significant.  Data were analyzed for 
normality and transformed if necessary.  Descriptive statistics were used for the 
demographics of the subjects.  The physical activity data, BP (brachial and central), 
arterial stiffness indices, and hemodynamic outcomes between the 2 groups (lean and 
obese) by 2 conditions (control and exercise) over the hour measurement period 
following exercise and pre post BP values will be assessed via Linear Mixed Models.  
The analysis will be conducted in a hierarchical fashion using Restricted Maximum 
Likelihood model and ‘variance components’ covariance error structure.  PEH used to 
predict chronic training BP changes will be calculated as the difference between pre-
exercise resting BP and the lowest 5-minute rolling average BP in the post-exercise 
period.  Pearson correlation will be used to assess the relationship between the magnitude 
of PEH from the first exercise session and the final resting BP value following aerobic 
training.   
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CHAPTER FOUR 
RESULTS 
Baseline Characteristics.  Twenty subjects (10 obese, 10 lean) started the 
intervention, four subjects, two from each group, dropped out for unrelated reasons 
resulting in 16 subjects, eight per group, completed the study.  Table 1 outlines the 
subject’s physical activity characteristics by group over the course of the two-week 
intervention and one week of baseline.  For daytime energy expenditure and steps, there 
was no group difference (P = 0.301, P = 0.936, respectively), week differences (P = 
0.978, P = 0.581, respectively), or group by week interaction (P = 0.807, P = 0.180, 
respectively).  There were significant group differences for minutes of moderate activity 
and vigorous activity per week between groups (P = 0.23, P = 0.001, respectively).  There 
was however no significant difference in time spent in moderate or vigorous activity over 
the course of the intervention and baseline period (P = 0.390, P = 0.587, respectively) and 
there was no significant group by week interaction (P = 0.757, P = 0.190, respectively). 
Table 2 details baseline demographic information by group.  There were no significant 
baseline differences for brachial SBP (BSBP) or DBP (BDBP), age, or VO2 peak (all P > 
0.05).  There were however, significant differences between groups for BMI, waist 
circumference, total body fat, and visceral fat (all P < 0.05).   
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Table 1. Physical activity characteristics by group over the course of the 
intervention and baseline period.  
  Baseline week 1 week 2 
Energy expenditure (Kcal/day)    
    
     Lean 2490 ± 631 2524 ± 511 2485 ± 465  
    
     Obese 2709 ± 404 2655 ± 412 2712 ± 475  
    
Steps    
    
     Lean 6517 ± 3823 6078 ± 3251  6585 ± 4025 
    
     Obese 6239 ± 2853  6465 ± 2547 5473 ± 2669 
    
Moderate activity (min/day)    
    
     Lean 66 ± 33 74 ± 29 67 ± 29 
    
     Obese 52 ± 24ᵅ 53 ± 21ᵅ 43 ± 23ᵅ 
    
Vigorous activity (min/day)    
    
     Lean 4 ± 4 3 ± 3 2 ± 3 
    
     Obese .5 ± 1ᵅ 1 ± .2ᵅ 1 ± 2 
ᵅRepresents significant group difference (P < 0.05)  
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Table 2. Demographic mean values ± SD (range) for subjects at rest by group.  
 Lean (n = 8) Obese (n = 8) P-value 
    
Brachial SBP (mm Hg) 126 ± 7 (22)   126 ± 5 (10)         0.976 
    
Brachial DBP (mm Hg) 76 ± 4 (15)    77 ± 7 (11) 0.567 
    
Age (yr) 24 ± 4 (19)    25 ± 4 (10) 0.547 
    
VO2peak (l.min
-1) 2.9 ± .4 (1.4)    3.2 ± .7 (2.0) 0.248 
    
BMI (kg/m2) 23 ± 2 (5)    34 ± 3 (8) < 0.001 
    
Weight (kg) 72 ± 19 (21) 104 ± 20 (64) < 0.001 
    
Waist (cm) 81 ± 3 (9) 133 ± 40 (102) 0.002 
    
Body fat (%) 23 ± 7 (17) 35 ± 2 (5) < 0.001 
    
Visceral fat (cm3) 279 ± 224 (605) 1471 ± 374 (1060) < 0.001 
 
Table 3 further outlines baseline resting hemodynamic characteristics between 
groups.  There were no baseline resting HR or central BP differences between groups (all 
P > 0.05).  Overall, obese PHTN was characterized by increased central arterial stiffness 
as witnessed by significant differences between groups for Ap (P < 0.001) and Aix @ HR 
75 (P = 0.002).  There was no PWV difference between groups.  As was hypothesized, 
the obese phenotype was characterized by a significantly higher CO (P = 0.005) and SV 
(P = 0.013) while the lean phenotype showed significantly higher SVR (P = 0.003).  
There were no resting group differences on cardiac index (l/min/m2), stroke volume index 
(ml/m2), and systemic vascular resistance index (Dyn.s/cm5.m2).  This suggests the 
differences seen between groups are due to body mass.    
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Table 3. Baseline hemodynamic characteristics by group. 
  Lean (n = 8) Obese (n = 8) P-value 
    
Central SBP (mm Hg) 110 ± 5 113 ± 6 0.123 
    
Central DBP (mm Hg) 77 ± 4 79 ± 7 0.316 
    
Ap (mm Hg) .63 ± 2 4.5 ± 4 0.001 
    
Aix @ HR 75 (%) -2.1 ± 7 
 
6.1 ± 12 0.02 
    
PWV (m/s) 6.0 ± .7 6.6 ± .8 0.237 
    
HR (bpm) 64 ± 10 66 ± 7 0.729 
    
CO (l/min) 4.7 ± 1 6.3 ± 1 0.005 
    
Ci (l/min/m2) 2.5 ± .4 2.7 ± .6 0.387 
    
SV (ml) 75 ± 15 101 ± 21 0.013 
    
Svi (ml/m2) 40 ± 7 42 ± 8 0.6 
    
SVR (Dyn.s/cm5) 1604 ± 444 1218 ± 263 0.003 
    
SVRi (Dyn.s/cm5.m2) 2956 ± 867 2783 ± 547 0.429 
Ci (cardiac index), Svi (Stroke volume index),  
SVRi (Systemic vascular resistance index) 
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Table 3. Acute exercise response between group before intervention (untrained) and 
following five exercise sessions (trained).  
  
 
 
Untrained baseline 
rest 
Untrained acute 
exercise response   
Trained 
baseline rest 
Trained 
acute 
exercise 
response   
BSBP (mm 
Hg)     
     
     Lean 127 ± 7 124 ± 7* 120 ± 13* 124 ± 8ᵝ 
     
     Obese 126 ± 5 130 ± 8ᵅᵅ 125 ± 11 127 ± 7 
     
BDBP (mm 
Hg)     
     
     Lean 76 ± 8 75 ± 6 73 ± 10* 74 ± 7 
     
     Obese 77 ± 11 76 ± 7 76 ± 12 75 ± 7 
     
CSBP (mm 
Hg)     
     
     Lean 110 ± 7 107 ± 5* 105 ± 12* 107 ± 8ᵝ 
     
     Obese 113 ± 6 116 ± 8ᵅᵅ 112 ± 11ᵅ 112 ± 7 
     
CDBP (mm 
Hg)     
     
     Lean 77 ± 4 77 ± 6 74 ± 11 75 ± 7 
     
     Obese 79 ± 7 78 ± 7 77 ± 11 75 ± 7 
     
Ap (mm Hg)     
     
     Lean 1 ± 2 -.8 ± 4* 
 
1 ± 7 .6 ± 4 
     
     Obese 5 ± 6ᵅ 6 ± 5ᵅᵅ 5 ± 8ᵅ 6 ± 5 
     
AIx (%)     
     
     Lean -2.4 ± 7 
 
-2.2 ± 7 
 
2 ± 12* 2 ± 8 
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     Obese 6 ± 12ᵅ 12 ± 8ᵅᵅ* 9 ± 13 13 ± 8 
     
PWV (m/s)     
     
     Lean 6.0 ± .7 5.8 ± .7 6.1 ± .8 6.1 ± .8 
     
     Obese 6.5 ± .9 6.5 ± .8 6.6 ± .8 6.7 ± .7 
     
HR (bpm)     
     
     Lean 64 ± 10 75 ± 11* 62 ± 11* 70±13**ᵝ 
     
     Obese 64 ± 7 72 ± 9*ᵅᵅ 67 ± 10ᵅ 72±10**ᵅᵅ 
     
SV (ml)     
     
     Lean 74 ± 13 74 ± 14 82 ± 16* 83 ± 19 
     
     Obese 106 ± 21ᵅ 102 ± 24*ᵅᵅ 99 ± 20* 94 ± 18**ᵅᵅ 
     
CO (L/min)     
     
     Lean 4.5 ± 1 5.4 ± 1* 5.0 ± 1* 5.7 ± 1** 
     
     Obese 6.7 ± 1ᵅ 7.2 ± 2*ᵅᵅ 6.5 ± 1*ᵅ 6.7± 1**ᵅᵅᵝ 
     
SVR 
(Dyn.s/cm5)     
     
     Lean 1605 ± 444 1381 ± 300* 1465 ± 299* 1361±533**ᵝ 
     
     Obese 1141 ± 263ᵅ 1066 ± 256*ᵅᵅ 1119 ± 339ᵅ 1110±341ᵅᵅᵝ 
*Significant difference from pre-trained baseline   
**Significant difference from trained baseline    
 ᵅSignificant between group differences    
ᵅᵅSignificant between group over time interactions   
ᵝSignificant within group pre-trained, trained over time interactions (all P < 0.05)  
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Table 4. Acute exercise response between group before intervention (untrained) and 
following five exercise sessions (trained). 
  
 
Untrained baseline 
rest 
Untrained acute 
exercise response   
Trained 
baseline 
rest 
Trained acute 
exercise 
response   
BSBP 
 (mm Hg)     
     
     Lean 127 ± 7 124 ± 7* 120 ± 13* 124 ± 8ᵝ 
     
     Obese 126 ± 5 130 ± 8ᵅᵅ 125 ± 11 127 ± 7 
     
BDBP  
(mm Hg)     
     
     Lean 76 ± 8 75 ± 6 73 ± 10* 74 ± 7 
     
     Obese 77 ± 11 76 ± 7 76 ± 12 75 ± 7 
     
CSBP 
 (mm Hg)     
     
     Lean 110 ± 7 107 ± 5* 105 ± 12* 107 ± 8ᵝ 
     
     Obese 113 ± 6 116 ± 8ᵅᵅ 112 ± 11ᵅ 112 ± 7 
     
CDBP  
(mm Hg)     
     
     Lean 77 ± 4 77 ± 6 74 ± 11 75 ± 7 
     
     Obese 79 ± 7 78 ± 7 77 ± 11 75 ± 7 
     
Ap 
 (mm Hg)     
     
     Lean 1 ± 2 
 
-.8 ± 4* 
 
1 ± 7 .6 ± 4 
     
     Obese 5 ± 6ᵅ 6 ± 5ᵅᵅ 5 ± 8ᵅ 6 ± 5 
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AIx (%) 
     Lean 
 
-2.4 ± 7 
 
 
-2.2 ± 7 
 
2 ± 12* 2 ± 8 
     
Obese                6 ± 12ᵅ 12 ± 8ᵅᵅ* 9 ± 13 13 ± 8 
     
PWV (m/s)     
     
     Lean               6.0 ± .7 5.8 ± .7 6.1 ± .8 6.1 ± .8 
     
     Obese               6.5 ± .9 6.5 ± .8 6.6 ± .8 6.7 ± .7 
     
HR (bpm)     
     
     Lean              64 ± 10 75 ± 11* 62 ± 11* 70 ± 13**ᵝ 
     
     Obese               64 ± 7 72 ± 9*ᵅᵅ 67 ± 10ᵅ 72 ± 10**ᵅᵅ 
     
SV (ml)     
     
     Lean             74 ± 13 74 ± 14 82 ± 16* 83 ± 19 
     
     Obese            106 ± 21ᵅ 102 ± 24*ᵅᵅ 99 ± 20* 94 ± 18**ᵅᵅ 
     
CO (L/min)     
     
     Lean             4.5 ± 1 5.4 ± 1* 5.0 ± 1* 5.7 ± 1** 
     
     Obese            6.7 ± 1ᵅ 7.2 ± 2*ᵅᵅ 6.5 ± 1*ᵅ 6.7 ± 1**ᵅᵅᵝ 
     
SVR 
(Dyn.s/cm5)     
     
     Lean          1605 ± 444 1381 ± 300* 1465±299* 1361.5±533**ᵝ 
     
     Obese           1141 ± 263ᵅ 1066 ± 256*ᵅᵅ 1119±339ᵅ 1110 ± 341ᵅᵅᵝ 
**Significant difference from trained baseline    
 ᵅSignificant between group differences    
ᵅᵅSignificant between group over time interactions   
ᵝSignificant within group pre-trained, trained over time 
interactions (all P < 0.05)  
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Acute Exercise Response.   Figure 3 illustrates that lean PHTN had a significant 
BSBP reduction averaging 3 ± 9 mm Hg (P = 0.014) following acute exercise while 
obese PHTN had a 3 mm Hg increase following an acute bout of exercise (P = 0.022).  
There was a significant 5 ± 8 mm Hg BSBP group difference over the course of the hour 
following exercise (P < 0.001).  There was also a significant BSBP group by time 
interaction (P = 0.021).  There was no significant BDBP or CDBP PEH, group over time 
change, or time by group interactions for either group (all P > 0.05).  Figure 4 shows that 
lean PHTN CSBP had a significant PEH effect, averaging a 3 ± 8 mm Hg reduction 
compared to pre-exercise values (P < 0.001) while obese PHTN had a 3 mm Hg CSBP 
increase (P = 0.018).  There was a significant group over time difference (P < 0.001) for 
CSBP with lean PHTN averaging 8 ± 8 mm Hg lower than obese PHTN.  There was also 
a significant group by time interaction for CSBP (P = 0.002).   
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Figure 5 shows a significant Ap reduction of 1.9 ± 5 mm Hg during the post 
exercise period for lean PHTN (P = 0.024) with a borderline significant increase in obese 
PHTN (P = 0.055).  There was also a significant mean group difference of 6 ± 5 mm Hg 
and a significant group by time interaction (P = 0.021).   Figure 6 shows a significant Aix 
@ HR 75 group difference of 14 ± 8% (P < 0.001) following exercise with a significant 
group by time interaction (P = 0.021).  There was no within group difference when 
comparing pre-exercise rest to post -exercise rest on Aix @ HR 75 for lean PHTN (P = 
0.672).  Obese PHTN showed a significant within group increase of approximately 6 ± 
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8% Aix @ HR 75 (P = 0.013).  There was a significant group by time interaction (P = 
0.004).  There was no significant post exercise PWV (m/s) change in lean PHTN (P = 
0.511) or obese PHTN (P = 0.945).  There was however a -.7 ± .7 m/s significant group 
difference over the course of the recovery period (P = 0.017).  There was no acute 
exercise group by time interaction for PWV (P = 0.835).  There were significant baseline 
differences, within group over time differences, and group by time interactions for SV 
(figure 7), CO (figure 8), and SVR (figure 9) between groups (all P < 0.001).  Figure 10 
shows that there were no HR group differences at rest (P = 0.467), during exercise (P = 
0.082) or during the recovery period (P = 0.483).  However, there was significant within 
group over time HR differences in both groups (P < 0.001) and a significant group by 
time interactions for HR (P = 0.023).    
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Table 5. Mean (± SD) resting values at baseline, 24 h and 48 h following the last 
training session between group.  
  Baseline 24 h following 48 h following  
Brachial SBP (mm Hg)    
    
     Lean 126 ± 7 122 ± 6* 122 ± 6* 
    
     Obese 126 ± 5 127 ± 6 127 ± 4ᵅ 
    
Brachial DBP (mm Hg)    
    
     Lean 76 ± 4 76 ± 6 76 ± 6 
    
     Obese 78 ± 7 74 ± 7 75 ± 8 
    
Central SBP (mm Hg)    
    
     Lean 110 ± 5 108 ± 5 107 ± 5* 
    
     Obese 113 ± 6 112 ± 6ᵅ 113 ± 6ᵅ 
    
Central DBP (mm Hg)    
    
     Lean 77 ± 4 77 ± 4 77 ± 4 
    
     Obese 80 ± 7 75 ± 7* 76 ± 7 
    
AP (mm Hg)    
    
     Lean .63 ± 2 .45 ± 2 .12 ± 2 
    
     Obese 4.5 ± 4ᵅ 4.9 ± 3ᵅ 4.3 ± 3ᵅ 
    
Aix (%)    
    
     Lean 
 
-2.1 ± 7 
 
 
-4.9 ± 7 
 
 
-5.0 ± 7 
 
    
     Obese 6.1 ± 12ᵅ 7.4 ± 9ᵅ 6.1 ± 11ᵅ 
    
59 
 
PWV (m/s)    
    
     Lean 6.0 ± .7 6.1 ± .9 6.0 ± .7 
    
     Obese 6.6 ± .8 6.6 ± .8 6.7 ± .8  
    
SV (ml)    
    
     Lean 75.1 ± 15 80.5 ± 13* 81.2 ± 14* 
    
     Obese 100.8 ± 21ᵅ 89.2 ± 19*ᵅ 92.2 ± 21**ᵅ 
    
HR (bpm)    
    
     Lean 64 ± 10 63 ± 11 63 ± 10* 
    
     Obese 66 ± 7 66 ± 9 64 ± 7* 
    
CO (L/min)    
    
     Lean 4.7 ± 1 5.0 ± 1* 5.0 ± 1* 
    
     Obese 6.3 ± 1ᵅ 5.8 ± 1*ᵅ 5.8 ± 1*ᵅ 
    
SVR (Dyn.s/cm5)    
    
     Lean 1604.3 ± 444 1435.5 ± 267* 1467.6 ± 296* 
    
     Obese 1218.2 ± 263ᵅ 1265.3 ± 270*ᵅ 1313.3±303**ᵅ 
*Significant difference from pre-trained baseline   
**Significant difference from 24 h following    
 ᵅSignificant between group differences (all P < 0.05)   
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Training adaptations.  Table 4 details the pre-trained acute and trained acute 
hemodynamic response for both groups.  Following exercise training, lean PHTN showed 
a significant increase in BSBP in response to acute exercise (P = 0.018) with no acute 
exercise response for obese PHTN (P = 0.152).  Trained baseline BSBP was significantly 
reduced from untrained baseline BSBP for the lean PHTN group (P = 0.022).  Figure 10 
shows lean PHTN BSBP response to acute exercise at a pre-trained state and a trained 
state.  If baseline BSBP is removed there is no significant lean PHTN BSBP difference 
between untrained and trained response (125 ± 6 mm Hg compared to 126 ± 9 mm Hg, P 
61 
 
= 0.584).  There was a significant training interaction from moving from untrained to 
trained for lean PHTN (P = 0.033).  There was a borderline significant within group pre-
trained to trained interaction for lean PHTN when examining CSBP (P = 0.058). Both 
groups witnessed a significant HR and SVR pre-trained to trained interaction in response 
to acute exercise (P < 0.001).  The obese group experienced a significant SV and CO pre-
trained to trained interaction in response to acute exercise (both P < 0.001).  
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Table 5 shows both within group and between group training effects.  Figure 11 
illustrates that lean PHTN witnessed a significant 4 mm Hg decrease in BSBP between 
baseline and 24 h post (P = 0.022) and a 3 mm Hg decrease between baseline and 48 h 
post (P = 0.039).  There were no significant changes for obese PHTN on BSBP (P = 
0.225).  There was a significant group by time interaction for BSBP (P = 0.020) 
insomuch that following training there were significant group differences in resting 
BSBP and CSBP.  The only DBP (central and brachial) training affect seen in either 
group was obese PHTN CDBP and this occurred 24 h following the last exercise session.  
Figure 12 shows a decrease with lean PHTN in CSBP between baseline and following 
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five training sessions (P = 0.007) and 48 h following the last exercise session (P = 0.049).  
There was no significant training effect in either group for Ap (P = 0.514), Aix (P = 
0.096), or PWV (P = 0.982).  Both SV and CO (Figure 13) were significantly increased at 
24 h and 48 h post training for lean PHTN (P < 0.001).  Within obese PHTN, SV and CO 
were significantly decreased at both 24 h and 48 h following the last training session (P < 
0.001).  HR significantly decreased by approximately 1 bpm only between baseline and 
48 h post last training session for both groups (P < 0.001).  SVR significantly decreased 
from baseline to 24 h and 48 h following the last session for lean PHTN while 
significantly increasing at 24 h and 48 h following the last training session for obese 
PHTN (both P < 0.001). 
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 Predictive power of PEH.  Figure 16 shows a significant association between the 
change in BSBP following acute exercise and the change in BSBP 48 h following the last 
exercise session (R = .577, P = 0.019).   There was only a trend for a significant 
association between change in BSBP 24 h following last exercise session and change in 
BSBP following acute exercise (R= .380, P = 0.147). 
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CHAPTER FIVE 
DISCUSSION  
 The primary aim of this study was to assess the impact of body phenotype on 
brachial BP and other central and peripheral hemodynamics in response to both acute and 
chronic exercise.  The main finding of this study was that PHTN men with a lean 
phenotype experience significant PEH, while obese PHTN men experienced increased 
BP acutely following exercise.  It was also found that the acute BP response to exercise 
foreshadowed what occurred in response to the short term training program.  Our work 
corroborates previous research showing associations between the acute and chronic 
exercise response (76).  Indeed, in the current study, with all subjects pooled together, a 
significant association was observed between PEH and chronic training reductions on 
BSBP.  Our research adds to what has been done by showing corresponding changes in 
CO and SVR.  
 An interesting finding from our study was the immediate post-exercise BP 
increase following the exercise session for both groups.  Posture has known effects on 
BP, in the current study subjects were asked to immediately lie supine following exercise.  
The supine position more than likely caused an increase CO due to increased volume 
returning to the heart, thus driving BP higher for 15 minutes following the exercise 
session.  Were our subject to have maintained a seated position this response more than 
likely would have not been see.  Even with this immediate increased BP, pressure still 
fell below baseline for the lean group. 
The observation that Ci, Svi, and SVRi, showed no differences between group at 
rest while CO, SV, and SVR did show differences between groups further support our 
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study design, suggesting that hemodynamic differences between our groups were likely 
dependent on body mass.  These resting hemodynamic differences between our groups, 
namely greater CO in the obese and increased SVR in the lean, have been documented by 
prior research (95, 131) and may help explain the divergent acute and chronic training 
responses seen.  As a consequence of reduced SVR, obese HTN subjects have been 
considered hemodynamically “younger” than lean HTN subjects. Paradoxically, studies 
suggest obese HTN individuals may suffer from fewer cardiovascular events when 
compared to their lean HTN counterparts (91, 100, 135, 220).  The precise theory as to 
why obese HTN individuals may be protected from cardiovascular events, namely a 
reduced SVR, may be the exact reason they did not respond favorably to exercise within 
the current trial.   
 In the majority of cases, indices of systemic and regional resistance are reduced 
below pre-exercise values during the PEH period (122).  Conversely, CO is most often 
elevated during the post-exercise period (71).  However, in different populations this may 
not be the case.  It has been documented in elderly men, that post-exercise SVR may 
actually increase (64).  Also, in endurance trained men CO has shown to decrease below 
pre-exercise values but not in women (182).  Except in endurance trained men (182), 
stroke volume remains unchanged during the PEH period following exercise (72).  This 
leads to the understanding that the mechanisms for PEH are different in heterogeneous 
populations.  Both lean and obese PHTN men responded to acute exercise with an 
increase in CO, primarily due to increased HR, and decreased SVR.  The driving force 
behind acute BP reductions to exercise is a reduction in SVR.  During exercise at 6 
METS for example,  SVR  has been predicted to fall to < 50% of resting levels (78).  It 
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seems plausible that counter regulatory mechanisms would be evoked if SVR decreased 
too much to maintain cerebral blood flow.  Indeed, acute cardiovascular collapse 
associated with loss of SVR is well recognized in many scenarios.  In our study, obese 
PHTN men experienced a mere 75 Dyn·s/cm5 reduction compared to a 224 Dyn·s/cm5 
reduction in lean PHTN men.  However, lean PHTN men had a significantly higher 
resting SVR when compared to the obese.     
A strength of our study was the additional measurements of central BP and central 
arterial stiffness.  Central BP is not only effected by CO and SVR, but also by measures 
of central arterial stiffness, pressure waveform, waveform timing, and waveform 
magnitude (87).  Because of this, changes in central BP and peripheral BP may not mimic 
each other.  At rest, there were no differences between groups on BSBP (126 mm Hg vs 
126 mm Hg, P = 0.976) but a trend for higher CSBP (113 mm Hg vs 110 mm Hg, P = 
0.123) with the obese was seen.  This is clinically relevant as central BP has been 
highlighted as a stronger measure than peripheral BP on predicting adverse 
cardiovascular outcomes (90, 171, 214).   
It has previously been shown that the obese are more likely to have increased 
arterial stiffness independent of peripheral BP levels (176).  This association may not be 
owing to obesity per se but central adiposity (51, 52).  As an indicator of obesity, we not 
only used BMI > 30 kg/m2, but also a waist circumference > 94 cm.  There were 
significant group differences on measures of visceral adiposity at rest, and visceral fat 
was correlated with resting brachial and central BP in addition to all measures of arterial 
stiffness.  Our obese subjects had significantly increased measures of Ap and Aix at rest 
when compared lean subjects.  Although PWV was not statistically increased in the obese 
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group, this is more than likely a matter of sample size, not clinical significance.  The .6 
m/s increase in PWV within our PHTN obese compared to the PHTN lean has been 
associated with an 8% increase in CV events and a 9% increase in CV mortality (7).  
These differences between groups are also clinically relevant as it is now understood that 
central arterial stiffness precedes the development of HTN (94, 223).   
The precise mechanisms that underlie the BP reduction in response to chronic 
exercise are not completely clear (23) owing to the complex etiology of HTN and 
dissimilarities across heterogeneous populations (23).  Clearly to achieve a peripheral BP 
reduction in response to exercise, either CO, SVR or a combination of both, must 
decrease.  Lean PHTN men saw significant reductions in both brachial and central SBP 
insomuch that following exercise training there were significant between group 
differences for both BSBP and CSBP.  Obese PHTN men saw no such reductions.  The 
reductions in BP for the lean group were accompanied with increased resting CO that was 
offset by the magnitude of reduction in resting SVR.  Obese PHTN men responded in a 
divergent manner with a decreased resting CO and increased resting SVR following our 
exercise training program.  This is congruent with previous literature showing that in 
response to aerobic exercise BP is reduced primarily due to decreased SVR (32). 
 Hemodynamic response to acute exercise changed in response to the subjects 
trained state.  For obese PHTN men, there was a significant training status by time 
interaction for CO due to a greater decrease in SV acutely following exercise in a trained 
state compared to untrained.  Obese PHTN also has a significant training status by time 
interaction for SVR insomuch that SVR did not decrease in response to acute exercise 
when in a trained state as it did in an untrained state.  The trained acute response to 
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exercise mimicked the chronic adaptations seen in obese PHTN men, i.e. increased 
resting SVR and decreased resting CO.  
 Lean PHTN men witnessed a significant training status by time interactions for 
BSBP and CSBP insomuch that both acutely increased following exercise in the trained 
state.  However, resting BP values for both central and peripheral SBP, as well as SVR 
were also significantly reduced from the pre-trained, pre-exercise resting values.  It has 
been shown that pre-exercise resting BP is one of the strongest predictors of PEH.  In 
fact, lean PHTN SVR achieved a lower absolute level when in a trained state compared to 
an untrained.  Figure 11 shows that when excluding baseline BP, the response to exercise 
in a trained or untrained state is not statistically different.   
The lack of reduction in central arterial stiffness values in response to aerobic 
training in either group is in accordance with prior literature.  A 2014 meta-analysis (7) 
established that aerobic training caused greater reductions in peripheral arteries (brachial-
ankle PWV) than with central arteries (cf-PWV) and those with stiffer arteries (PWV >8 
m/s) saw greatest reductions in PWV.  In our study central arterial stiffness was measured 
and our group of men had values of 6 m/s for lean and 6.6 m/s for obese.  In addition, 
training that lasted longer than 10-weeks showed the best benefit on PWV, while ours 
lasted merely two. 
The divergent findings between obese and lean PHTN in response to acute and 
chronic exercise cannot be explained beyond the hemodynamic properties that were 
measured in this study, namely SVR.  It has been hypothesized that dysfunctional adipose 
tissue cause changes in secretion of adiponectin and leptin that could negatively impact 
SVR and sympathetic nervous system activity (61, 152).  It has also been shown that 
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obesity increases renal sodium absorption due to increased sympathetic nervous system 
activity (69).  These do not however explain why SVR increased in response to exercise 
training while SV decreased in obese PHTN males.    
 A strength of our study was the use of activity monitors to control for outside 
physical activity behaviors that may influence our results.  There was no difference at rest 
or over the course of the three-week device-wearing period for energy expenditure or 
steps taken.  The lean group had a significantly increased time spent in moderate activity 
by approximately 14 – 24 min/day and a significantly increased level of vigorous activity 
by about 1 – 4 min/day.  This is not likely to affect the study outcomes.  The subjects 
showed consistent physical activity behavior over the course of the baseline period and 
study intervention.  The Sensewear device has also been shown to overestimate time 
spend in moderate activity (13).  We also showed that measured fitness levels between 
group were not significantly different, confirming the sedentary nature of our subjects.  
Our study is not without weaknesses. The outcomes measured are impacted by a 
multitude of factors, one being diet and fluid intake.  Although diet records were given to 
the subjects to record dinner the night before and breakfast the morning of measurement 
visits, it is possible that subjects were inconsistent with diet intake.  Subjects were asked 
to monitor fluid intake by consuming liquids from a bottle of a known quantity and to 
keep this quantity the same for each measurement visit.  The integrity of this request 
relied with the subjects to comply.  We also did not measure other factors associated with 
BP change such as catecholamines, sympathetic nervous system activation, renin 
aldosterone angiotensin system, or adipokines that could give further insight into 
phenotypic differences in response to exercise.  For example, A 2012 paper by Halliwill 
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et al. (70) indicated that much of the PEH can be explained by histaminergic vasodilation, 
primarily due to the H1 and H2 receptors within the muscle.  Combined H1 and H2 
receptor antagonism reduced post-exercise vasodilation by roughly 80% and reduced 
PEH by 65% (70).  To the authors knowledge there is no research illustrating possible 
differences between obese and lean on histaminergic activation.  Future studies need to 
be designed and conducted to measure more precisely the mechanisms responsible for 
SVR findings in our study.  
In conclusion, upwards of 25% of those who engage in an exercise program with 
the goal of decreasing BP are considered “non-responders” (17).  It has been found that  
12% of people actually increase BP (> 10 mm Hg) in response to exercise training (16).  
These data illustrate the critical need to identify factors that explain the heterogeneity of 
exercise response on BP.  In the current study, every lean subject, except one (see figure 
16), had a favorable brachial SBP response to chronic exercise raining.  Only one obese 
subject had a training brachial SBP reduction. Considering body phenotype may be a 
simple way to predict the efficacy of an aerobic exercise program with the goal to reduce 
BP.  This study should be considered as a pilot study and future research with increased 
sample sizes that could explore why body size may affect BP response to exercise need to 
be conducted.   
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